SeqOne in France buying Sanger spin-out Congenica to create world leader in AI-powered genomic medicine
The buyer, based in Montpelier, is a pioneer in AI-driven genomic analysis and the acquisition will create the largest global ‘software pure player’ in the genomics space, serving over 160 labs in more than 30 countries. The deal terms will remain undisclosed.
Founded in 2012, Congenica is said to bring a legacy of deep clinical expertise and experience servicing more than 25 private and public labs, including multiple NHS Genomics Laboratory Hubs and key national initiatives such as Genomics England and the Hong Kong Genomic Program.
SeqOne provides clinical decision-support tools that enable molecular laboratories to deliver fast, accurate, and scalable analysis of genetic data for applications in oncology, rare and inherited conditions and infectious diseases.
The acquisition unites SeqOne’s AI-powered platform for Next-Generation Sequencing analysis with Congenica’s trusted clinical decision support technology and clinical interpretation services. The integrated offering will transform complex genomic data into rapid, actionable insights, ultimately accelerating diagnosis for families affected by rare disease and enabling more precise, personalised cancer therapies.
The move comes at a critical inflection point in medicine. The cost to sequence a human genome has plummeted, creating a data tsunami. For hospitals and labs worldwide, the challenge is no longer generating data, but interpreting it. This ‘interpretation bottleneck’ is the single biggest barrier to delivering personalised medicine, and it can only be solved with highly intelligent software.
“The rapid pace of personalised medicine demands continuous investment in software innovation and deep specialisation,” said Martin Dubuc, CEO of SeqOne.
“By integrating Congenica’s world-class team, we are further enhancing our strong growth trajectory and ability to provide market-leading software to customers, expert interpretation services, and deepening our presence in the UK – a global leader in clinical genomics since the landmark 100,000 Genomes Project.”
The acquisition comes on the heels of a period of intense organic growth for SeqOne, which has seen the company double its revenue and expand its international presence from three to over 30 countries in just 12 months.
It also follows the successful acquisition of Life & Soft in April, which expanded the company's capabilities into multi-omics and virology. This momentum, supercharged by a recent €20 million funding round from top-tier VCs, has enabled SeqOne to execute its strategy to consolidate a fragmented market and build the definitive software operating system for the clinical genomics revolution.
The combined entity will have a significantly expanded global footprint and will comprise a dedicated team of more than 125 employees – enabling over 200,000 patient genomic analyses in 2025. That's a threefold increase over 2024. SeqOne confirms that it will maintain what it calls a meaningful UK presence at Sanger.
Dr. Richard Scott, Chief Executive Officer at Genomics England, commented: “Congenica has been an instrumental partner to Genomics England, particularly in advancing rare disease diagnosis through their robust platform for clinical whole genome analysis.
“We look forward to continuing this important work with the combined expertise of the SeqOne team to deliver benefits for patients.”
“The Board of Congenica is proud of the immense impact our technology has had on healthcare since our inception, Dr Andy Richards, Chairman of Congenica, added: “We support this combination with SeqOne, believing their vision and resources are best positioned to carry that legacy forward and ensure our innovative platform continues to thrive and serve patients globally.”
